A Phase 3, Open Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661 in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous or Heterozygous for the F508del CFTR Mutation
Phase of Trial: Phase III
Latest Information Update: 11 Feb 2017
At a glance
- Drugs Ivacaftor (Primary) ; Tezacaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Vertex Pharmaceuticals
- 02 Dec 2016 Planned End Date changed from 1 Mar 2017 to 1 Sep 2018.
- 02 Dec 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Sep 2018.
- 09 Nov 2016 New trial record